BACKGROUND: Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen. Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo. The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines. RESULTS: Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group. Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 months vs. 4.8 months from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001). Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression. Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2. An interim analysis of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P=0.75). CONCLUSIONS: Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer. Interim analysis showed no overall survival benefit. The toxicity profile of olaparib in this population was consistent with that in previous studies. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT00753545.).
BACKGROUND: Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen. Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo. The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines. RESULTS: Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group. Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 months vs. 4.8 months from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001). Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression. Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2. An interim analysis of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P=0.75). CONCLUSIONS: Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer. Interim analysis showed no overall survival benefit. The toxicity profile of olaparib in this population was consistent with that in previous studies. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT00753545.).
Authors: George Au-Yeung; Franziska Lang; Walid J Azar; Chris Mitchell; Kate E Jarman; Kurt Lackovic; Diar Aziz; Carleen Cullinane; Richard B Pearson; Linda Mileshkin; Danny Rischin; Alison M Karst; Ronny Drapkin; Dariush Etemadmoghadam; David D L Bowtell Journal: Clin Cancer Res Date: 2016-09-23 Impact factor: 12.531
Authors: Jung-Min Lee; Cody J Peer; Minshu Yu; Lauren Amable; Nicolas Gordon; Christina M Annunziata; Nicole Houston; Andrew K L Goey; Tristan M Sissung; Bernard Parker; Lori Minasian; Victoria L Chiou; Robert F Murphy; Brigitte C Widemann; William D Figg; Elise C Kohn Journal: Clin Cancer Res Date: 2016-09-23 Impact factor: 12.531
Authors: Brian D Gonzalez; Sharon L Manne; Jerod Stapleton; Shannon Myers-Virtue; Melissa Ozga; David Kissane; Carolyn Heckman; Mark Morgan Journal: Support Care Cancer Date: 2016-10-19 Impact factor: 3.603
Authors: Chaoyang Sun; Yong Fang; Jun Yin; Jian Chen; Zhenlin Ju; Dong Zhang; Xiaohua Chen; Christopher P Vellano; Kang Jin Jeong; Patrick Kwok-Shing Ng; Agda Karina B Eterovic; Neil H Bhola; Yiling Lu; Shannon N Westin; Jennifer R Grandis; Shiaw-Yih Lin; Kenneth L Scott; Guang Peng; Joan Brugge; Gordon B Mills Journal: Sci Transl Med Date: 2017-05-31 Impact factor: 17.956
Authors: Yi Kan Wang; Ali Bashashati; Michael S Anglesio; Dawn R Cochrane; Diljot S Grewal; Gavin Ha; Andrew McPherson; Hugo M Horlings; Janine Senz; Leah M Prentice; Anthony N Karnezis; Daniel Lai; Mohamed R Aniba; Allen W Zhang; Karey Shumansky; Celia Siu; Adrian Wan; Melissa K McConechy; Hector Li-Chang; Alicia Tone; Diane Provencher; Manon de Ladurantaye; Hubert Fleury; Aikou Okamoto; Satoshi Yanagida; Nozomu Yanaihara; Misato Saito; Andrew J Mungall; Richard Moore; Marco A Marra; C Blake Gilks; Anne-Marie Mes-Masson; Jessica N McAlpine; Samuel Aparicio; David G Huntsman; Sohrab P Shah Journal: Nat Genet Date: 2017-04-24 Impact factor: 38.330